3.2.2 OutcomesafteracutetreatmentBe

3.2.2 OutcomesafteracutetreatmentBetween-group effect sizes for continuous measures of target disor- der symptoms from pre- to posttreatment were in the medium range (Hedges’ g = 0.56, 95% CI = 0.44–0.69, P < .0001), indicating superior improvement in individuals randomized to CBT over placebo. Effect sizesweresignificantlysmallerforITTsamples(Hedges’ g = 0.40,95%CI = 0.25–0.56, P < .0001) compared to completer samples (Hedges’ g = 0.70,95%CI = 0.54–0.86, P < .0001; QB = 6.85,df = 1, P < .01).The OR for categorical measures of treatment response of CBT compared to placebo condition was 2.97 (95% CI = 2.15–4.10, P < .0001). ORs were again larger for completer samples (OR = 3.69, 95% CI = 2.59– 5.26, P < .0001) than ITT (OR = 2.42, 95% CI = 1.65–3.54, P < .0001), however this difference was not significant (QB = 2.56, df = 1, P = n.s.; seeFigures2and3foraforestplotofeffectsizesandORsofeachindi- vidualstudyincludedintheanalysis).

結果 (繁體中文) 1:

3.2.2 Outcomesafteracutetreatment

組間效應尺寸的從預治療後到目標disor- DER症狀連續措施是中等範圍（樹籬'G = 0.56，95％CI = 0.44-0.69，P <0.0001），表明在個人良好的改進隨機分配到CBT超過安慰劑。效果sizesweresignificantlysmallerforITTsamples（樹籬'G = 0.40,95％
相比完成者樣品CI = 0.25-0.56，P <0.0001）（樹籬'G = 0.70,95％CI = 0.54-0.86，P <0.0001; QB = 6.85，DF = 1，P <0.01）。該OR為與安慰劑相比，條件CBT的治療反應的分類措施是2.97（95％CI = 2.15-4.10，P <0.0001）。OR值分別為完成者的樣品（OR = 3.69，95％CI = 2.59- 5.26，P <0.0001）比ITT（OR = 2.42，95％CI = 1.65-3.54，P <0.0001），但是這種差異較大再次不顯著（QB = 2.56，DF = 1，P = NS; seeFigures2and3foraforestplotofeffectsizesandORsofeachindi- vidualstudyincludedintheanalysis）。

結果 (繁體中文) 2:

3.2.2 急性治療後的結果

從預治療到治療後連續測量目標脫毛症狀的組間效應大小在中等範圍內（Hedges' g = 0.56，95% CI = 0.44±0.69，P = .0001），表明隨機到CBT的個體比安慰劑有優越的改善。影響大小明顯小於ITT樣本（對沖 g = 0.40，95%
CI = 0.25±0.56，P = .0001）與完整樣品相比（對沖 g = 0.70，95%CI = 0.54±0.86，P = .0001;QB = 6.85，df = 1，P = .01）。與安慰劑狀況相比，CBT治療反應的OR為2.97（95%CI = 2.15~4.10，P = .0001）。完全樣品的 OR 再次更大（OR = 3.69，95% CI = 2.59= 5.26， P = .0001） 比 ITT（OR = 2.42，95% CI = 1.65±3.54，P = .0001），但是這種差異並不顯著（QB = 2.56，df = 1，P = n.s.;參見圖2和3inaofaindi- 包括分析中的二維研究）。

結果 (繁體中文) 3:

3.2.2 TeracuteTreatment的結果
從治療前到治療後，連續量測靶點二聚體症狀的組間效應大小在中等範圍內（Hedges'g=0.56，95%CI=0.44-0.69，P<0.0001），表明隨機接受CBT的個體比安慰劑有更好的改善。效應大小對小顆粒孔樣品影響顯著（Hedges'g=0.40,95%
與完整樣本（Hedges'g=0.70,95%CI=0.54-0.86，P<0.0001；QB=6.85，df=1，P<0.01）相比，CBT治療反應分類名額的OR值為2.97（95%CI=2.15-4.10，P<0.0001）。對於更完整的樣本（OR=3.69，95%CI=2.59-5.26，P<0.0001），ORs再次大於ITT（OR=2.42，95%CI=1.65-3.54，P<0.0001），但這種差异並不顯著（QB=2.56，df=1，P=n.s；參見圖2和圖3，分析中包含的機器的影響大小和研究結果）。